0001209191-23-016392.txt : 20230306
0001209191-23-016392.hdr.sgml : 20230306
20230306170816
ACCESSION NUMBER: 0001209191-23-016392
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230302
FILED AS OF DATE: 20230306
DATE AS OF CHANGE: 20230306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lieu Hsiao D
CENTRAL INDEX KEY: 0001468482
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38853
FILM NUMBER: 23709828
MAIL ADDRESS:
STREET 1: C/O NGM BIOPHARMACEUTICALS, INC.
STREET 2: 333 OYSTER POINT PKWY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER NAME:
FORMER CONFORMED NAME: Lieu Hsiao
DATE OF NAME CHANGE: 20090716
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NGM BIOPHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001426332
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-243-5555
MAIL ADDRESS:
STREET 1: 333 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-02
0
0001426332
NGM BIOPHARMACEUTICALS INC
NGM
0001468482
Lieu Hsiao D
C/O NGM BIOPHARMACEUTICALS, INC.
333 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
SVP, Chief Medical Officer
Common Stock
2023-03-02
4
A
0
53000
0.00
A
55605
D
Stock Option (Right to Buy)
4.36
2023-03-02
4
A
0
159000
0.00
A
2033-03-01
Common Stock
159000
159000
D
Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
Includes 1,352 shares acquired under the Issuer's Employee Stock Purchase Plan (the "ESPP") on November 15, 2021, 1,252 ESPP shares acquired on May 13, 2022 and 1 ESPP share acquired on November 15, 2022.
The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.
/s/ Valerie Pierce, Attorney-in-fact
2023-03-06